Level C· Early human research exploring benefitsCase Report / SeriesPubMed

Autologous stromal vascular fraction cells: a tool for facilitating tolerance in rheumatic disease.

Ichim TE., Harman RJ., Min WP., Minev B., Solano F., Rodriguez JP.

Case Report / Series on Autoimmune Research, published in Cell Immunol (2010) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Case Report / Series
Journal
Cell Immunol (2010)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
20537320
DOI
10.1016/j.cellimm.2010.04.002
Citations
23

Abstract (original English)

Since the days of Medawar, the goal of therapeutic tolerogenesis has been a "Holy Grail" for immunologists. While knowledge of cellular and molecular mechanisms of this process has been increasing at an exponential rate, clinical progress has been minimal. To provide a mechanistic background of tolerogenesis, we overview common processes in the naturally occurring examples of: pregnancy, cancer, oral tolerance and anterior chamber associated immune deviation. The case is made that an easily accessible byproduct of plastic surgery, the adipose stromal vascular fraction, contains elements directly capable of promoting tolerogenesis such as T regulatory cells and inhibitory macrophages. The high content of mesenchymal and hematopoietic stem cells from this source provides the possibility of trophic/regenerative potential, which would augment tolerogenic processes by decreasing ongoing inflammation. We discuss the application of this autologous cell source in the context of rheumatoid arthritis, concluding with some practical examples of its applications.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Adipose TissueAgedAnimalsArthritis, RheumatoidAutoantibodiesCells, CulturedFemaleHematopoietic Stem Cell TransplantationHumansJoints

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research